Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dongsheng Tu

Showing results (21-30 of 200) with videos related to

Pageof 20
Sort By:
Pharmaceutical Statistics|November 23, 2020
Joint analysis of longitudinal measurements and survival times with a cure fraction based on partly linear mixed and semiparametric cure modelsLu Yang, Hui Song, Yingwei Peng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2003
neu/erbB-2 overexpression and response to hormonal therapy in premenopausal women in the adjuvant breast cancer setting: will it play in Peoria? part IIKathleen I Pritchard, Mark N Levine, Dongsheng Tu
Statistics in Medicine|April 19, 2019
Quantile regression and empirical likelihood for the analysis of longitudinal data with monotone missing responses due to dropout, with applications to quality of life measurements from clinical trialsYang Lv, Guoyou Qin, Zhongyi Zhu, et al.
Contemporary Clinical Trials|April 5, 2021
Estimation of the binomial probabilities in a two-stage phase II clinical trial with two co-primary endpointsYiming Sun, Xinyi Zhang, Xianming Tan, et al.
Lifetime Data Analysis|November 3, 2009
Confidence intervals for the first crossing point of two hazard functionsMing-Yen Cheng, Peihua Qiu, Xianming Tan, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|April 2, 2021
Factors predicting missing instruments in three cancer randomized clinical trialsMichael J Palmer, Harriet Richardson, Dongsheng Tu, et al.
Statistics in Medicine|March 29, 2022
Multiply robust subgroup analysis based on a single-index threshold linear marginal model for longitudinal data with dropoutsKecheng Wei, Huichen Zhu, Guoyou Qin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approvalJohn Goffin, Stefan Baral, Dongsheng Tu, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
NCIC Clinical Trials Group experience of employing patient-reported outcomes in clinical trials: an illustrative study in a palliative settingMichael Brundage, Andrea Bezjak, Dongsheng Tu, et al.
Anesthesia and Analgesia|January 20, 2009
A randomized, double-blind, controlled trial of perioperative administration of gabapentin, meloxicam and their combination for spontaneous and movement-evoked pain after ambulatory laparoscopic cholecystectomyIan Gilron, Elizabeth Orr, Dongsheng Tu, et al.
Pageof 20

Showing results (21-30 of 200) with videos related to

Sort By:
Pageof 20
Pharmaceutical Statistics|November 23, 2020
Joint analysis of longitudinal measurements and survival times with a cure fraction based on partly linear mixed and semiparametric cure modelsLu Yang, Hui Song, Yingwei Peng, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2003
neu/erbB-2 overexpression and response to hormonal therapy in premenopausal women in the adjuvant breast cancer setting: will it play in Peoria? part IIKathleen I Pritchard, Mark N Levine, Dongsheng Tu
Statistics in Medicine|April 19, 2019
Quantile regression and empirical likelihood for the analysis of longitudinal data with monotone missing responses due to dropout, with applications to quality of life measurements from clinical trialsYang Lv, Guoyou Qin, Zhongyi Zhu, et al.
Contemporary Clinical Trials|April 5, 2021
Estimation of the binomial probabilities in a two-stage phase II clinical trial with two co-primary endpointsYiming Sun, Xinyi Zhang, Xianming Tan, et al.
Lifetime Data Analysis|November 3, 2009
Confidence intervals for the first crossing point of two hazard functionsMing-Yen Cheng, Peihua Qiu, Xianming Tan, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation|April 2, 2021
Factors predicting missing instruments in three cancer randomized clinical trialsMichael J Palmer, Harriet Richardson, Dongsheng Tu, et al.
Statistics in Medicine|March 29, 2022
Multiply robust subgroup analysis based on a single-index threshold linear marginal model for longitudinal data with dropoutsKecheng Wei, Huichen Zhu, Guoyou Qin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approvalJohn Goffin, Stefan Baral, Dongsheng Tu, et al.
Expert Review of Pharmacoeconomics & Outcomes Research|June 10, 2010
NCIC Clinical Trials Group experience of employing patient-reported outcomes in clinical trials: an illustrative study in a palliative settingMichael Brundage, Andrea Bezjak, Dongsheng Tu, et al.
Anesthesia and Analgesia|January 20, 2009
A randomized, double-blind, controlled trial of perioperative administration of gabapentin, meloxicam and their combination for spontaneous and movement-evoked pain after ambulatory laparoscopic cholecystectomyIan Gilron, Elizabeth Orr, Dongsheng Tu, et al.
Pageof 20